Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KYMR

Kymera Therapeutics Inc

Sep 12 • 04:00PM ET

46.99

+0.79 1.71 %

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI VB IWM VBK VXF XBI IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.48	Insider Own	17.41%	Shs Outstand	70.56M	Perf Week	8.00%
Market Cap	3.36B	Forward P/E	-	EPS next Y	-4.04	Insider Trans	7.91%	Shs Float	59.05M	Perf Month	15.37%
Enterprise Value	2.78B	PEG	-	EPS next Q	-0.74	Inst Own	94.97%	Short Float	13.83%	Perf Quarter	-0.63%
Income	-275.43M	P/S	75.15	EPS this Y	-11.94%	Inst Trans	13.87%	Short Ratio	11.59	Perf Half Y	40.48%
Sales	44.71M	P/B	3.41	EPS next Y	-21.05%	ROA	-28.15%	Short Interest	8.16M	Perf YTD	16.80%
Book/sh	13.77	P/C	5.05	EPS next 5Y	-13.70%	ROE	-33.26%	52W High	53.27 -11.79%	Perf Year	0.23%
Cash/sh	9.31	P/FCF	-	EPS past 3/5Y	-12.62% -26.36%	ROIC	-26.39%	52W Low	19.44 141.66%	Perf 3Y	64.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-13.54% 74.20%	Gross Margin	81.87%	Volatility	3.86% 4.52%	Perf 5Y	59.02%
Dividend TTM	-	EV/Sales	62.18	EPS Y/Y TTM	-44.09%	Oper. Margin	-697.51%	ATR (14)	1.93	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.32	Sales Y/Y TTM	-49.51%	Profit Margin	-616.03%	RSI (14)	63.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.32	EPS Q/Q	-65.42%	SMA20	9.04%	Beta	2.22	Target Price	62.21
Payout	-	Debt/Eq	0.09	Sales Q/Q	-55.26%	SMA50	8.10%	Rel Volume	0.82	Prev Close	46.20
Employees	188	LT Debt/Eq	0.07	Earnings	Aug 11 BMO	SMA200	21.84%	Avg Volume	704.64K	Price	46.99
IPO	Aug 21, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.28% -48.40%	Trades		Volume	579,356	Change	1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform

Show Previous Ratings

Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Loading…
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)
Jul-09-25 06:02AM	Morgan Stanley Puts These 2 Stocks on Its Buy List Heres Why You Should Follow (TipRanks)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
04:16AM	Loading…
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 11:56PM	Kymera Therapeutics Announces Pricing of $250 Million Public Offering (GlobeNewswire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 04:05PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
01:04PM	Gilead eyes Kymeras adhesive cancer drug in $750m deal (Pharmaceutical Technology)
08:07AM	Kymera adds Gilead as research partner, while advancing new candidate with Sanofi (BioPharma Dive)
07:05AM	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update (GlobeNewswire)
07:00AM	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders (Business Wire)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-06-25 03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
Jun-05-25 04:16PM	Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial (Barrons.com) +7.68%
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
02:22AM	Loading…
02:22AM	Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 10:29AM	Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response (Benzinga) +45.51%
07:44AM	Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
May-30-25 04:01PM	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 (GlobeNewswire)
May-29-25 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.03%
May-19-25 12:15PM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference (GlobeNewswire)
May-10-25 07:00AM	Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-25 09:26AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings (GuruFocus.com) +5.70%
May-07-25 07:00AM	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference (GlobeNewswire)
Apr-25-25 06:03PM	Why Kymera Therapeutics Stock Crushed it This Week (Motley Fool)
Apr-24-25 07:00AM	Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 (GlobeNewswire) +9.32%
Apr-22-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader (GlobeNewswire) +6.04%
Apr-10-25 10:10AM	Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? (Zacks) -6.47%
Apr-09-25 07:00AM	Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer (GlobeNewswire) +13.78%
Feb-28-25 02:15AM	Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
Feb-27-25 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -14.45%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-26-25 07:33AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-20-25 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-30-25 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-15-25 09:38AM	Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? (Zacks) +8.57%
Jan-14-25 01:28PM	Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments (GuruFocus.com) +7.79%
07:00AM	Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-07-25 07:00AM	Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 (GlobeNewswire)
Dec-27-24 04:25PM	Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal (TipRanks)
Nov-26-24 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-05-24 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-24 03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 08:40AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-30-24 09:10AM	Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-24-24 10:01AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases (GlobeNewswire)
Oct-23-24 07:15AM	Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium (GlobeNewswire)
Oct-09-24 07:00AM	Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Sep-25-24 07:00AM	Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? (Zacks)
Aug-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-21-24 11:15AM	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-24 01:02PM	Kymera (KYMR) to Raise $225 Million Through Offering of Shares (Zacks)
07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 10:45PM	Kymera Therapeutics Announces Pricing of $225 Million Public Offering (GlobeNewswire)
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Aug-08-24 09:55AM	Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-07-24 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 (GlobeNewswire) +7.17%
Jul-10-24 08:10AM	Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains? (Zacks) -8.09%
Jul-09-24 01:30PM	Why Kymera Therapeutics Stock Is Soaring Today (Motley Fool) +23.40%
12:22PM	Kymera Therapeutics soars as Sanofi expands phase 2 trials (Investing.com)
10:44AM	Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug (Investopedia)
09:59AM	Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies (Zacks)
07:00AM	Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day (GlobeNewswire)
Jul-08-24 04:05PM	Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy (GlobeNewswire) +5.65%
Jun-20-24 08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
Jun-14-24 07:00AM	Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire)
Jun-01-24 08:00AM	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-29-24 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-23-24 05:00PM	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-22-24 11:20AM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) -8.52%

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BVF PARTNERS L P/IL	Director	Jun 30 '25	Buy	44.00	317,167	13,955,348	2,798,795	Jul 01 06:41 PM
BAKER BROS. ADVISORS LP	Director	Jun 30 '25	Buy	44.00	655,500	28,842,000	6,117,295	Jun 30 08:15 PM
Ridloff Elena	Director	Jun 11 '25	Option Exercise	20.29	4,500	91,305	4,500	Jun 11 04:47 PM
Ridloff Elena	Director	Jun 11 '25	Sale	50.00	4,500	225,000	0	Jun 11 04:47 PM
ELENA RIDLOFF	Director	Jun 11 '25	Proposed Sale	48.60	4,500	218,700		Jun 11 04:26 PM
Esposito Pamela	Director	Jun 03 '25	Option Exercise	29.55	5,000	147,750	5,000	Jun 03 06:30 PM
Esposito Pamela	Director	Jun 03 '25	Sale	49.04	5,000	245,186	0	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Option Exercise	27.67	12,000	332,040	12,000	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Sale	46.10	12,000	553,200	0	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Option Exercise	2.08	30,000	62,400	690,482	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Sale	49.00	30,000	1,470,000	660,482	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Option Exercise	10.34	6,349	65,649	6,349	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Sale	49.00	6,349	311,101	0	Jun 03 06:30 PM
Mainolfi Nello	Officer	Jun 03 '25	Proposed Sale	49.00	30,000	1,470,000		Jun 03 04:31 PM
JEFFREY ALBERS	Director	Jun 03 '25	Proposed Sale	43.13	6,349	273,832		Jun 03 04:25 PM
PAMELA ESPOSITO	Director	Jun 03 '25	Proposed Sale	43.13	5,000	215,650		Jun 03 04:25 PM
ELENA RIDLOFF	Director	Jun 03 '25	Proposed Sale	43.13	12,000	517,560		Jun 03 04:24 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '25	Sale	29.30	2,575	75,436	66,420	May 23 04:30 PM
Chadwick Jeremy G	Officer	May 23 '25	Proposed Sale	30.17	2,575	77,688		May 23 04:20 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 31 '25	Option Exercise	2.08	25,000	52,000	226,886	Apr 01 08:00 AM
Chiniara Ellen	Chief Legal Officer	Mar 03 '25	Sale	30.45	2,241	68,239	80,085	Mar 03 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 03 '25	Sale	30.45	1,383	42,113	67,800	Mar 03 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 03 '25	Sale	30.45	7,035	214,219	201,886	Mar 03 06:30 PM
Gollob Jared	Chief Medical Officer	Mar 03 '25	Sale	30.45	5,740	174,786	120,000	Mar 03 06:30 PM
Gollob Jared	Officer	Mar 03 '25	Proposed Sale	31.35	5,740	179,949		Mar 03 06:00 PM
Chiniara Ellen	Officer	Mar 03 '25	Proposed Sale	31.35	2,241	70,255		Mar 03 06:00 PM
Chadwick Jeremy G	Officer	Mar 03 '25	Proposed Sale	31.35	1,383	43,357		Mar 03 06:00 PM
Jacobs Bruce N.	Officer	Mar 03 '25	Proposed Sale	31.35	7,035	220,547		Mar 03 06:00 PM
Mainolfi Nello	Chief Executive Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	659,959	Jan 13 07:00 AM
Jacobs Bruce N.	Chief Financial Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	178,921	Jan 13 07:00 AM
Chiniara Ellen	Chief Legal Officer	Jan 06 '25	Sale	41.75	3,129	130,645	54,826	Jan 06 05:00 PM
Chiniara Ellen	Officer	Jan 06 '25	Proposed Sale	41.59	3,129	130,135		Jan 06 04:30 PM
Esposito Pamela	Director	Dec 02 '24	Option Exercise	29.55	2,500	73,875	2,500	Dec 02 07:50 PM
Esposito Pamela	Director	Dec 02 '24	Sale	49.00	2,500	122,500	0	Dec 02 07:50 PM
PAMELA ESPOSITO	Director	Dec 02 '24	Proposed Sale	46.85	2,500	117,125		Dec 02 04:41 PM
Esposito Pamela	Director	Sep 17 '24	Option Exercise	23.86	13,500	322,075	13,500	Sep 17 06:20 PM
Esposito Pamela	Director	Sep 17 '24	Sale	48.28	13,500	651,766	0	Sep 17 06:20 PM
PAMELA ESPOSITO	Director	Sep 17 '24	Proposed Sale	48.48	13,500	654,480		Sep 17 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYMR

Kymera Therapeutics Inc

Upgrade your FINVIZ experience